| Literature DB >> 26906637 |
Kendra R Vann1, Yavuz Ergün2, Sevil Zencir3, Serkan Oncuoglu2, Neil Osheroff4, Zeki Topcu5.
Abstract
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is an antineoplastic agent that intercalates into DNA and alters topoisomerase II activity. Unfortunately, this compound displays a number of adverse properties. Therefore, to investigate new ellipticine-based compounds for their potential as topoisomerase II-targeted drugs, we synthesized two novel derivatives, N-methyl-5-demethyl ellipticine (ET-1) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2). As determined by DNA decatenation and cleavage assays, ET-1 and ET-2 act as catalytic inhibitors of human topoisomerase IIα and are both more potent than the parent compound. Neither compound impairs the ability of the type II enzyme to bind its DNA substrate. Finally, the potency of ET-1 and ET-2 as catalytic inhibitors of topoisomerase IIα appears to be related to their ability to intercalate into the double helix.Entities:
Keywords: Anticancer drugs; Catalytic inhibitor; DNA cleavage; DNA intercalation; DNA topoisomerase IIα; Ellipticine derivatives
Mesh:
Substances:
Year: 2016 PMID: 26906637 PMCID: PMC4785065 DOI: 10.1016/j.bmcl.2016.02.034
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823